Business Description
Outlook Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US69012T2069
Description
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.98 | |||||
| Equity-to-Asset | -1.78 | |||||
| Debt-to-Equity | -0.39 | |||||
| Debt-to-EBITDA | 25.57 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 22.8 | |||||
| 3-Year EPS without NRI Growth Rate | 29 | |||||
| 3-Year FCF Growth Rate | 26.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 55.58 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 21.76 | |||||
| 9-Day RSI | 21.43 | |||||
| 14-Day RSI | 23.88 | |||||
| 6-1 Month Momentum % | -19.55 | |||||
| 12-1 Month Momentum % | -36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.07 | |||||
| Quick Ratio | 1.07 | |||||
| Cash Ratio | 0.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -27 | |||||
| Shareholder Yield % | -151.85 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -229.89 | |||||
| ROIC % | -155.68 | |||||
| ROC (Joel Greenblatt) % | 103.82 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | 41.15 | |||||
| EV-to-EBITDA | 38.06 | |||||
| EV-to-Forward-Revenue | 5.78 | |||||
| EV-to-FCF | -0.75 | |||||
| Earnings Yield (Greenblatt) % | 2.43 | |||||
| FCF Yield % | -134.42 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Outlook Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -9.933 | ||
| Beta | -1.61 | ||
| Volatility % | 81.92 | ||
| 14-Day RSI | 23.88 | ||
| 14-Day ATR (€) | 0.399163 | ||
| 20-Day SMA (€) | 4.526 | ||
| 12-1 Month Momentum % | -36 | ||
| 52-Week Range (€) | 0.845 - 9.52 | ||
| Shares Outstanding (Mil) | 23.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Outlook Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Outlook Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Outlook Therapeutics Inc Frequently Asked Questions
What is Outlook Therapeutics Inc(FRA:41O)'s stock price today?
The current price of FRA:41O is €1.56. The 52 week high of FRA:41O is €9.52 and 52 week low is €0.85.
When is next earnings date of Outlook Therapeutics Inc(FRA:41O)?
The next earnings date of Outlook Therapeutics Inc(FRA:41O) is 2024-12-20 Est..
Does Outlook Therapeutics Inc(FRA:41O) pay dividends? If so, how much?
Outlook Therapeutics Inc(FRA:41O) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers